Tranexamic acid structure
|
Common Name | Tranexamic acid | ||
---|---|---|---|---|
CAS Number | 1197-18-8 | Molecular Weight | 157.210 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 300.2±15.0 °C at 760 mmHg | |
Molecular Formula | C8H15NO2 | Melting Point | >300 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 135.4±20.4 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Tranexamic acidTranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: OthersTranexamic acid is a synthetic derivative of the amino acid lysine. Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding.Toxicity/Adverse event: Rare in general, including gastrointestinal effects, dizziness, fatigue, headache, and hypersensitivity reactions. Use of tranexamic acid has a potential risk of thrombosis. |
Name | tranexamic acid |
---|---|
Synonym | More Synonyms |
Description | Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: OthersTranexamic acid is a synthetic derivative of the amino acid lysine. Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding.Toxicity/Adverse event: Rare in general, including gastrointestinal effects, dizziness, fatigue, headache, and hypersensitivity reactions. Use of tranexamic acid has a potential risk of thrombosis. |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 300.2±15.0 °C at 760 mmHg |
Melting Point | >300 °C(lit.) |
Molecular Formula | C8H15NO2 |
Molecular Weight | 157.210 |
Flash Point | 135.4±20.4 °C |
Exact Mass | 157.110275 |
PSA | 63.32000 |
LogP | 0.31 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.497 |
Water Solubility | 1G/6ML |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi:Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | 26-36-37/39 |
RIDADR | UN 1993 3/PG 2 |
WGK Germany | 2 |
RTECS | GU8400000 |
Packaging Group | II |
Hazard Class | 3 |
HS Code | 2922499990 |
~% Tranexamic acid CAS#:1197-18-8 |
Literature: US3950405 A1, ; |
~% Tranexamic acid CAS#:1197-18-8 |
Literature: Journal of Computer-Aided Molecular Design, , vol. 27, # 7 p. 615 - 635 |
Precursor 0 | |
---|---|
DownStream 10 | |
HS Code | 2922499990 |
---|---|
Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |
Long-Term Mild, rather than Intense, Exercise Enhances Adult Hippocampal Neurogenesis and Greatly Changes the Transcriptomic Profile of the Hippocampus.
PLoS ONE 10 , e0128720, (2015) Our six-week treadmill running training (forced exercise) model has revealed that mild exercise (ME) with an intensity below the lactate threshold (LT) is sufficient to enhance spatial memory, while i... |
|
Design, Synthesis, and Photophysical Properties of Pyrroloquinoline-Based Compounds Showing Strong Blue Fluorescence as Potential Dyes for Biomedical Applications.
ChemMedChem 10 , 1846-62, (2015) A small library of 3-ethylpyrrolo[3,2-f]quinoline derivatives was synthesized to identify a novel class of dyes for use in biological studies. According to the spectroscopic analyses performed to eval... |
|
Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.
Acta Pharmacol. Sin. 35(6) , 846-52, (2014) Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer. To overcome its poor water solubility, we constructed lapatinib-inc... |
(1R,2R)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride (1:1) |
trans-Tramadol hydrochloride |
Amstat |
trans-4-(Aminomethyl)cyclohexane-carboxylic acid |
Cyclohexanecarboxylic acid, 4- (aminomethyl)-, trans- |
Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-, hydrochloride (1:1) |
UNII:9N7R477WCK |
Tramadol hydrochloride |
tranexamic acid |
Tranexamic EP Impurity B |
Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- |
trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid |
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid |
Tramadol HCL |
(1R,2R)-2-[(diméthylamino)méthyl]-1-(3-méthoxyphényl)cyclohexanol chlorhydrate |
AMCA,AMCHA,HAKU |
cis-Tranexamic Acid |
cis-4-(Aminomethyl)-1-cyclohexanecarboxylicacid |
(+)-tramadol hydrochloride |
CIS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLICACID |
trans-4-(Aminomethyl)cyclohexanecarboxylic acid |
cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-, hydrochloride |
MFCD00001466 |
trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid |
EINECS 214-818-2 |